After several years of operating out of Ramat Gan, the company made a real estate leap by moving to Herzliya’s high-tech district - one of Israel’s most sought-after office hubs. The new ...

Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a ...

Boehringer Ingelheim has released data on its patient reach, sales, and investments during 2024, and is looking ahead to the company’s anticipated offerings for the rest of 2025. In a press release on ...

Dublin, April 22, 2025 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: Boehringer Ingelheim 2025" company profile has been added to ResearchAndMarkets.com's offering. The report ...

Markus Schümmelfeder has spent more than a decade looking for ways to help biopharmaceutical giant Boehringer Ingelheim exploit digital and data. He joined the company in February 2014 as ...

The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilise challenging drug targets from Boehringer Ingelheim’s drug discovery programs to enable ...

“We are excited to collaborate with the innovative teams at Boehringer Ingelheim,” said Jens Frauenfeld, CEO of Salipro Biotech. “By combining our Salipro ® platform technology with Boehringer ...

Cognizant, as the prime system integrator, began the Boehringer Ingelheim project by codeveloping a program roadmap, agile methodology, and implementation workflow. The overall scope of the ...

Feb 25 (Reuters) - Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung ...

Hyderabad, Telangana, India: Boehringer Ingelheim India has signed a Memorandum of Understanding (MoU) with Hyderabad-based EMRI Green Health Services a GVK enterprise, the operator of the ...

Boehringer Ingelheim's schizophrenia drug candidate has failed in clinical trials, leading to the discontinuation of further research. Global pharmaceutical company Boehringer Ingelheim noted on ...

Boehringer Ingelheim, is a biopharmaceutical company active in both human and animal health, announced that the company is adding an innovative preclinical programme with the acquisition of Nerio ...